Tirzepatide is a dual GIP/GLP-1 receptor agonist and the most heavily characterised weekly incretin in Australian research literature. Full profile inside.
Tirzepatide is a 39-residue synthetic peptide engineered from the GIP backbone with substitutions that confer GLP-1 receptor cross-activity. A C20 fatty diacid supports the once-weekly research administration interval published in SURPASS and SURMOUNT protocols. Average mass ~4813.5 Da.
Dual mechanism
- GIP receptor agonism — adipocyte insulin sensitivity and lipid handling.
- GLP-1 receptor agonism — glucose-dependent insulin, satiety, gastric emptying.
- DPP-4-resistant backbone modifications preserve activity across the dosing interval.
Published titration reference
| Week | Reference weekly dose |
|---|---|
| 1–4 | 2.5 mg |
| 5–8 | 5 mg |
| 9–12 | 7.5 mg |
| 13–16 | 10 mg |
| 17–20 | 12.5 mg |
| 21+ | 15 mg |
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
Research use only. All information on this page is provided strictly for in-vitro and laboratory research reference. Nothing in this article is medical, therapeutic, dosing, or performance advice for human or veterinary use.
